In analgesic drug development, one pattern has become hard to ignore: drug candidates that "look effective" in animal models frequently fail once they enter human clinical trials.
The cause is not always molecular design, target selection, or the clinical protocol. A growing number of retrospective analyses point to a factor that sat outside the discussion for a long time: how pain is defined and measured in the preclinical stage.
1. Pain Is Far More Than A Simple Metric
In many traditional preclinical models, pain is simplified into a handful of numbers:
- Hot-plate latency
- Tail-flick latency
- Mechanical stimulation threshold
- A few scores on a behavioral rating scale
These metrics, widely used in rodent models, have supported the development logic for a generation of painkillers. The problem is what they actually capture: these indicators measure a "reflex," not the "experience of pain."
In a clinical setting, pain is never single-dimensional. It simultaneously includes:
- Sensory components (stimulus intensity, threshold)
- Motor impact (impaired mobility, changes in weight-bearing)
- Emotional responses (anxiety, aversion, avoidance)
- Cognitive and memory aspects (conditioned place avoidance, long-term impact)
Isolating a small fraction of that experience and expecting it to predict the whole of human pain is how a program ends up with a drug that performs in the laboratory and disappoints in the clinic.
2. The Translational Gap: Why "Effective in Animals" Doesn't Mean "Effective in Humans"
A look back at failed drug programs reveals a recurring structural problem:
The preclinical stage validates a "stimulus-reflex" response, while the clinical stage must address "perception-emotion-decision."
During animal testing, an analgesic candidate might successfully:
- Increase the latency of a thermal stimulus response
- Improve a specific behavioral score
- Perform well under short-term, acute stimulation
In the clinic, the same drug often fails to improve the patient's:
- Mobility and daily activity levels
- Sleep quality
- Pain-related emotional distress
- Overall long-term quality of life
That outcome does not make the molecule useless. It more often means that the preclinical phase never tested the dimensions where the drug needed to work, and no amount of statistical power on the wrong endpoint repairs that. The divergence is structural: a spinal withdrawal reflex is organized below the level where attention, expectation, and descending inhibition act, and those processes decide how much a patient suffers from a given stimulus.
3. The Evolution Of Pain Models: From Single Endpoints To Systemic Characterization
Over the past few years, a clear trend has emerged in pain research: assessment is shifting from single endpoints to a multidimensional, systemic combination of endpoints.
The logic behind the shift is straightforward:
- Pain is not a momentary event but a continuous state.
- Pain reshapes behavioral patterns, not just triggers reflexes.
- The emotional and memory components of pain determine the risk of it becoming chronic.
Consequently, more R&D teams are beginning to focus on:
- Spontaneous behavioral changes (rather than passive responses to stimuli)
- Motor and weight-bearing patterns (to measure functional impact)
- Avoidance and conditioned learning (to assess emotion and memory)
- Neurophysiological signals (EEG, fMRI, and other translatable biomarkers)
No single model covers all four. A focused design such as Pain Mechanisms: The UVB Sunburn Model Is A Vital Translational Tool answers one part of the question well, and the study plan has to say which part it is answering.
The change is not about "increasing experimental complexity" for its own sake. It is about reducing the probability of translational failure, and about producing a dataset that a clinical team can argue from rather than around.
4. Why Non-Human Primate (NHP) Models Are Gaining Prominence
During this transition, the importance of non-human primate (NHP) models has become increasingly evident.
The reasons are clear:
- Their central nervous system structure is much closer to that of humans.
- Their behavioral and emotional responses are more complex and stable.
- They allow for long-term, continuous assessments that more closely mimic clinical scenarios.
They support the evaluation of endpoints like facial expression (grimace scales) and conditioned learning, both of which are difficult to score in a rodent over weeks. Grimace scoring is one of the few read-outs with a direct clinical counterpart, since the criteria were first described in patients and then adapted for animals. Scoring them consistently is a separate problem, and the approach is described under AI-based NHP Behavior Analysis System.
NHP models turn "pain" from a passive reaction into a state that can be observed and characterized over time.
This allows researchers to move beyond asking:
- "Does the animal react to the stimulus?"
- And start asking:
- "Has the pain altered its behavior, decision-making, and daily rhythms?"
That is a different level of information about the same animal, gathered without adding a stimulus.
5. A New Paradigm: From Blocking Pain Signals To Improving Function
The core questions driving analgesic R&D are changing.
In the past, programs focused on:
- Did the drug raise the pain threshold?
- Did it shorten the reaction time?
Now, the questions look like this:
- Does it improve mobility and activity?
- Does it reduce pain-related avoidance behaviors?
- Does it alleviate the negative emotional burden of pain?
- Is it effective against the multifaceted nature of chronic pain?
These questions cannot be answered by a single endpoint. They require a pain assessment ecosystem that mirrors clinical reality, which is the argument made in Multi-Endpoint Pain Assessment: The Future Of Analgesic Drug Development.
6. Rethinking Pain Assessment Is Rethinking Risk Management
When an analgesic program reaches a critical development milestone, the assessment that matters is often about more than generating "one more positive result." It is about asking:
- Are we measuring endpoints that truly matter to patients?
- Are these endpoints clinically translatable and interpretable?
- If the drug fails, will that failure provide valuable information?
From this perspective, upgrading your preclinical pain model is not an increase in cost, it is an exercise in front-loading and mitigating risk. A program that learns at month six what it would otherwise learn at Phase II has bought time, and the cost of the extra endpoint is small against the cost of a failed trial.
Final Thoughts
The difficulty in developing new analgesics stems not only from target complexity but also from how "pain" itself is understood and measured.
When pain is treated as a multidimensional, continuous state deeply integrated with behavior and emotion, the logic of preclinical study design has to follow, and the endpoint list is where that shows up first.
For the next generation of analgesic R&D, this is the step that cannot be skipped.
